



Overview

- Mission and Vision
- Background
- Comparative Advantage and Value
- Past Performance
- Contract research efforts
- Morehouse SoM Team Combined Capabilities





Mission


We exist to: i) improve the health and well-being of individuals and communities; ii) increase the diversity of the health professional and scientific workforce; and iii) address primary health care through programs in education, research, and service

Vision

Leading the creation and advancement of health equity.




Morehouse SoM Programs at a Glance




27 products in development and 200 patents

6) Post-market surveillance

Leveraging Capabilities, Technologies, and Services



Contract Research & Service Capabilities




Email: jlillard@msm.edu



TRANSLATIONAL TECHNOLOGIES MOREHOUSE SCHOOL OF MEDICINE

Past Performance – Research & Training Funding

Figure from April 2016




- FY16: \$56,509,022 with a breakdown of \$47,360,863 from continuing grants, \$8,797,409 as new awards and competitive renewals representing \$350,750.
- FY15: \$44,597,475 with a breakdown of \$30,445,880 from continuation grants, \$11,051,595 as new awards and competitive renewals represent \$3,100,000 of the total.

Email: jlillard@msm.edu



Past Performance – Intellectual Property Created



Email: jlillard@msm.edu




Past Performance – Contracts with Large/Medium Businesses

- Health IT & Analytics Subcontract Services
 - <u>Awarded</u> DoT-IRS TIPSS4 exclusive HBCU/MI partner with Northrop Grumman (deal valued at \$2m/yr for 10 yrs)
 - <u>Awarded</u> Navy Omnibus 3 exclusive HBCU/MI partner with General Dynamics (deal valued at \$1m/yr for 5 yrs)
 - Awarded HHS CIO-SP3 LB exclusive HBCU/MI partner with SRA Intl
 - <u>Awarded</u> HHS CIO-SP3 SB exclusive HBCU/MI partner with PSI Intl
 - Not Awarded DHS Eagle III exclusive HBCU/MI partner with PSI Intl
 - Not Awarded CDC and NCI nutritional survey with Reveal Analytics
- Life Sciences Subcontract Services
 - <u>Awarded</u> nine SBIR/STTR subcontract awards
- Clinical & Social Subcontract Services
 - <u>Awarded</u> NIH OD OT2OD025284-01 "All of Us"
 - <u>Awarded</u> NIH Fogarty D43TW009340 "UJMT Global Consortium"



Past Performance – contracts with Small Businesses **Commercialization & Industry Engagement**

- 12 Morehouse SoM technologies have been licensed to small to mid-size businesses that have raised over \$80 million in private equity.
- Four of these companies were awarded \$2.2 million in SBIR/STTR grant awards. Morehouse SoMassociated companies lead the state of Georgia in STTR funding in 2013 and 2014.
- \$850,000 SBIR/STTR subcontracts awarded to Morehouse SoM





Detailed Summary of Commercialization Efforts

Nine Faculty startups and Three Partnerships (focus & track record)

- <u>4DGenome 13' (Song)</u>: chromosome-specific haplotyping software and single cell isolation equipment (\$225,000 SBIR award)
- AccuHealth Technologies 12' (Ofili): app for chronic disease care & clinical trials
- **<u>Akumba Diagnostics 13' (Stiles)</u>**: saliva-based tests for parasitic infections
- BrainGEN 13' (Ford): neuregultin/chimeras to treat CNS injuries and stroke IVD
 - **Complexa 11' (Chen):** synthetic nitro fatty acid (CXA-10) to treat acute renal injury (completed Phase I trial after raising *\$21 million* in funding). Enrolling subjects for Phase II clinical study.
- Heat Biologics 08' (Pattillo): clinical-stage company developing cell-based immunotherapy for the treatment of a wide range of cancers. Raised *\$48 million* through IPO.
- Haplomics 11' (Lillard): rFVIII and therapies for African American hemophilia A patients (\$575,000 from two STTR and one SBIR awards).
- JYANT Technologies 10' (Lillard, R Gonzalez, R Singh, S Singh): chemokine/chemokine receptor/obesity receptor antagonists and nanotechnologies for cancer, inflammatory diseases, and their diagnosis (*\$1.2 million from one SBIR and three STTR awards*).
- **Orunmil Pharma 15' (Bond)**: mortalin/HSP65 peptide inhibitor to treat cancers, inflammatory disease, and viral infections.
- **Nutriglobal 12' (Hibbert)**: medicinal foods for sickle cell anemia and cachexia.
- <u>R & Z, Inc. 14' (Xiong/Simon)</u> & Shenzhen Anshide Asset Co Ltd 16': peptide and small molecule ASIC1a inhibitors for CNS injuries associated with acidosis.



Email: jlillard@msm.edu

Haplomics

eat Biolo

4DGENOME, INC.

Brain- Gen

Ο

ccuhea

AKUSA

Comp





NutriGlobal S, Inc.

R&ZINC.

SBIR/STTR Awards to Date

AWARD	PROJECT NAME	PI/FACULTY NAME(S)	TOTAL AWARD AMOUNT	PROJECTED AWARD TO MSM
4DGenome R43HG007621-01	Cost-effective and high-throughput chromosomal haplotyping	Song	\$218,556	\$65,567
Exscien Corporation R41NS086267-01A1	Enhancing mtDNA Repair During Stroke Reperfusion to Reduce Brain Damage	Wilson / Simon	\$149,171	\$59,668
Haplomics R41MD008156-01A1	Evaluation of the Antigenicity of Restricted FVIII Haplotypes	Lillard	\$184,545	\$73,818
Haplomics R41MD008809-01	Novel Pharmacogenomic Approach for Identifying T Cell Epitopes in Replacement FVIII Therapy	Lillard	\$203,848	\$81,539
Haplomics R43MD008660-01	H3 FVIII for Hemophilia A Patients at High Risk for Anti-Drug Antibodies	Lillard	\$243,349	\$97,34 0
JYANT Technologies R43DK096857-01A1	Treatment of Colitis and Ileitis using a Novel CXCR3 Biologic Antagonist	Lillard / R Singh	\$317,247	\$126,898
JYANT Technologies R41CA183399-01A1	Novel adjuvant therapy for triple negative breast cancer	Gonzalez / Lillard	\$225,000	\$90,000
JYANT Technologies R41MD010320-01	Anti-CXCL13 mAb to mitigate prostate cancer health disparities	S Singh / Lillard	\$315,320	\$126,128
JYANT Technologies R41CA214080-01	Anti-CCL25 mAb to treat castration resistant prostate cancer	S Singh / Lillard	\$315,320	\$126,128
		TOTAL	\$2,172,356	\$847,086



Contract Research & Service Capabilities

Strategically Partnering to Add Depth and Breadth

Information Technology (Health IT) Services







Medical, Life Sciences, & Environmental Services





Healthcare & Social Services



Email: jlillard@msm.edu



TRANSLATIONAL TECHNOLOGIES MOREHOUSE SCHOOL OF MEDICINE


Working Example: *Precision Medicine Initiative in Oncology*



Right Patient Right Treatment Right Time

Prevactions Fight Patient, Prevactics Fight Patient, Portiging and the states of the second s

Power of Integrating Big Data



- Ability to discover new biomarkers & drug targets
- Enhanced ability to match patient to right treatment or clinical trial
- Superior data set for clinical decision-making
- Improved ability to track & understand patient treatments, outcomes & costs





For more information contact: James Lillard, PhD MBA Associate Dean for Research Affairs Director of the Office of Translational Technologies Morehouse School of Medicine 720 Westview Drive SW Atlanta, GA 30310-1495 Email: jlillard@msm.edu





- Pioneering breakthroughs in Biomedical Research for nearly 70 years
- Over 400 active grants and contracts (700+ active and closed annually)
- Submits **30 contract applications per month**
- Broad expertise in toxicology, pharmacology, gene therapy, on clinical trials
- Development of novel models of infectious disease (emerging pathogens), Alzheimer's disease, and cancer
- Increasing focus on Pharmaceutical R&D, dosing paradigms, endpoints
- Facilities, staff, processes needed to support all study aspects
- Successfully administer commercial and federal grants and contracts





- Employs a mix of skill sets to include-engineers, scientists, programmers, technicians, logisticians and administrative personnel
- Working on Three Continents
- High-end Engineering, Software Services & Logistics Support
- SENTEL's is a recognized provider of innovative products, imaginative solutions and quality services, with five core pillars of competency: Engineering Services, Mission Support, Information Technology, Logistics and Business Support Services
- ISO 9001:2008 Certification and CMMI Level II Certification





Antibody Discovery Multiple Technology Platforms, Antigen Creation, Hybridoma Development, Hybridoma Cloning & Screening, High-throughput Hybridoma Sequencing, Phage Library Construction & Screening, and Single B-Cell Cloning LakePharma **Cell Line Development & Culture Ontimization** Stable Cell Line Development, Tegrated Solution Research Cell Banking, Media Adaptation, Cell Culture Optimization, and Custom Media Development

Molecular Biology

Plasmid Design, Gene Synthesis, Cloning, DNA Sequence Analysis, Transfection-Grade Plasmid Production, and Virus Generation

Protein Engineering & Production

Antibody Humanization, Affinity Maturation, de novo Antibody Sequencing, Proprietary High-expression Vectors, Expression Using Microbial, Mammalian, Insect & Yeast Systems, Production of Proteins, Antibodies, Antibody-like Molecules & **Fusion Proteins, and Purification** Process Development & Scale-up

Bioanalytics

Affinity Measurement (Octet, Blacore) and **Biophysical Characterization including Intact Mass** (LC-MS), Sequence Confirmation, Post Translational Modification, Protein Aggregation (SE-HPLC), Thermostability (DSC), Particle Size (DLS), Charge Variation (IEX), pl, RP-HPLC, CE-SDS, and Formulation & Stability Analysis

Biochemical and Cell-based Assay Development & Screening, Radioligand Binding, ELISAs, Meso Scale Discovery Assays, High Content Screening. Proliferation & Viability Assays, Flow Cytometry, and gPCR

Translating protein drug or biomarker into final product



Email: jlillard@msm.edu



Million Veteran Program: A Partnership with Veterans



- Founded in 2010, biorepository and genomics company based in Atlanta
- State of the art automation and robotics with suite of genomics platforms
- Operates in 14,000 sq. ft. purpose built laboratories and offices
- More than 120,000 samples processed in 2014
- Performs to high regulatory standards
- CLIA/CAP compliant Biorepository services: biobanking to regulatory standards, DNA/RNA extraction, QC & quantitation services, genomics services, assay development services for customers, informatics, molecular cytogenomics testing
- Awarded Veteran's Affairs MVP Contract





Background

- Established: May 3, 2004 ۲
- Certifications: SBA (A) / 8a
- SWaM
- Dunns/Cage: 825333961
- 53FF5
- Headquarters: 7001 Loisdale Road, Suite C45, Springfield, VA 22150
- www.supremesolutionsinc.com

Services

- 9 Program Management
- Markov Acquisition Support
- Information Technology
- Mesearch & Development





- Over 17 years of experience working in research administration.
- Expert knowledge of application guide lines for SBIR/STTR submissions.
- Submitted thousands of applications to numerous federal agencies.
- SBIR/STTR Pre and Post Award Management

